Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wilate prophylaxis in previously treated patients with severe hemophilia A
2016-003681-34Phase 3Completed
- Sponsor
- Octapharma
- Start
- Nov 2016
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of von Willebrand factor concentrate in hemophilia A, sponsored by Octapharma. Primary endpoint: Total annualized bleeding rate reduction. Started Nov 2016; status: completed.
02
Drugs
von Willebrand factor concentrate
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2016-003681-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003681-34.